Download Files:
CNX-774
$100 – $850
Products Details
Product Description
– CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification[1][2].
Web ID
– HY-13943
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C26H22FN7O3
References
– [1]Matthew Labenski, et al. In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton’s Tyrosine Kinase.|[2]Akintunde Akinleye, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59.
CAS Number
– 1202759-32-7
Molecular Weight
– 499.50
Compound Purity
– 99.46
SMILES
– O=C(NC)C1=NC=CC(OC2=CC=C(NC3=NC=C(F)C(NC4=CC=CC(NC(C=C)=O)=C4)=N3)C=C2)=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 45 mg/mL
Target
– Btk
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
